Figure 1

Characterization of T-cell responses against MAGE-C2/CT10. (a) Percentages of seven patients showing T-cell responses (black bars=CD4⁺, white bars=CD8⁺) against a given peptide epitopes of MAGE-C2/CT10 as assessed by IFN-γ ELISPOT. (b) Exemplary IFN-γ ELISPOT of a MAGE-C2/CT10-specific T-cell line after exposure to the cognate peptide MAGE-C2_351–370 (left) or control peptide SSX-2_91–110 (right). (c) Perforin ELISPOT of bulk T cells from patient UKE-1207 after exposure to the cognate MAGE-C2/CT10 antigen (left, pool of peptides MAGE-C2_251–270 to MAGE-C2_291–310) or control peptide SSX-2_91–110. (e) Peptide titration experiment for the assessment of antigen affinity of two MAGE-C2/CT10-specific CD4⁺ T-cell clones. The mean number of IFN-γ spots after exposure to the cognate (black dots) or control peptide (open dots) is indicated. (d) Exemplary FACS dot blot of a MAGE-C2/CT10-specific CD4⁺ T-cell clone after exposure to the cognate peptide MAGE-C2_101–120 (left) or control peptide SSX-2_91–110 (right). Intracellular IFN-γ production is shown on the x-axis.